Stock listing

Satellos Bioscience Inc

Selected listing: MSCL · NEO · CAD · CA

Satellos Bioscience Inc (Cboe Canada: MSCL), Health Technology. Latest release Oct 5, 2026: Satellos Granted Composition of Matter Patent for Forazapadin.

MSCL:NEOCADCAUpdated October 2, 2026

Ticker: Cboe Canada: MSCL
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Cboe Canada
Currency: CAD

About Satellos Bioscience Inc

The company focuses on developing innovative therapies for muscle diseases. Its research and development efforts aim to address unmet medical needs in this area.

Latest news from Satellos Bioscience Inc

Satellos Granted Composition of Matter Patent for Forazapadin

October 5, 2026

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

September 30, 2026

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

September 24, 2026

Satellos to Present at the 31st Annual Congress of the World Muscle Society

September 15, 2026

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

September 9, 2026

All Satellos Bioscience Inc news →

Research Satellos Bioscience Inc

Satellos Bioscience Inc company profile

View the public company page for Satellos Bioscience Inc on 6ix.

Satellos Bioscience Inc news

Read company news and market updates connected to Satellos Bioscience Inc.

Satellos Bioscience Inc investor events

Find investor webinars, events, and replay context for Satellos Bioscience Inc.